Related Experiment Video
Updated: Jul 19, 2026

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017
Sodium metavanadate affected control and streptozotocin-diabetic rat liver golgi complexes
Wojciech Dabroś1, Anna Goc, Bohdan Turyna
1Department of Pathomorphology, Jagiellonian University Collegium Medicum, Kraków. mpdabros@cyf-kr.edu.pl
Abstract:
As we have observed previously, rat liver Golgi complexes are very useful cell organelle in investigating the effectiveness of various drugs with cytoprotective or normalizing activities in streptozotocin (STZ)-induced diabetes. The diabetes-associated biochemical and morphological alterations in the organelle were investigated in four groups of rats: control and STZ-diabetic (C and D groups) and compared with the same groups treated with 1.5 mM metavanadate administered as drinking solutions in 0.09 M NaCl over 7 days (C+V and D+V groups). Apart from the untreated group C, a decrease of body weight during the experiment was noted in the remaining three groups, reaching a statistically significant level in the diabetic groups (c. 15%). Fluid and food intake were statistically significantly (p<0.001) limited in both the vanadium treated groups. In the diabetic group treated with metavanadate, the free blood sugar level decreased, but euglycemia was not achieved. In groups C+V, D and D+V, the activity of Golgi marker enzyme, i.e. galactosyltransferase (GalT), was statistically lower as compared with group C (p<0.001). The treatment of diabetic rats with 1.5 mM NaVO3 [V(V)I in 0.09 M NaCl as a drinking solution during 7 days did not normalize the yield of Golgi membrane preparations or the Golgi marker enzyme activity. Electron microscopy revealed marked ultrastructural changes triggered by the employed vanadium compound. A striking change was seen in the presence of giant intracytoplasmic vacuoles. These alterations were seen in both experimental groups, i.e. C+V and D+V. Group C+V showed more advanced ultrastructural changes, what was expressed in a poorer state of mitochondrial membranes, a greater number of vesicular structures and less frequently seen Golgi structures. In spite of the fact that the animals were exposed to two compounds with a strong biological activity, the group of diabetic rats treated with metavanadate (D+V) showed no such advanced changes: more numerous Golgi structures were noted and their form was practically ring-like, i.e. characteristic for this group of organelles.
Insights
Metavanadate treatment in diabetic rats did not normalize Golgi enzyme activity or blood sugar levels. However, it did reduce severe ultrastructural damage in liver Golgi complexes, suggesting a protective role against diabetes-induced cellular changes.
Area of Science:
- Biochemistry
- Cell Biology
- Endocrinology
Background:
- Streptozotocin (STZ)-induced diabetes causes significant biochemical and morphological alterations in rat liver Golgi complexes.
- Golgi complexes serve as a valuable model for assessing drugs with cytoprotective or normalizing effects in diabetes.
Purpose of the Study:
- To investigate the effects of metavanadate on STZ-induced diabetic rat liver Golgi complexes.
- To evaluate metavanadate's impact on Golgi marker enzyme activity and ultrastructure in diabetic models.
Main Methods:
- Four groups of rats were used: control (C), STZ-diabetic (D), control treated with metavanadate (C+V), and diabetic treated with metavanadate (D+V).
- Metavanadate (1.5 mM) was administered in drinking solution for 7 days.
- Evaluations included body weight, fluid/food intake, blood glucose, Golgi galactosyltransferase (GalT) activity, and electron microscopy for ultrastructural analysis.
Main Results:
- Metavanadate treatment reduced body weight loss and fluid/food intake in diabetic rats, but did not achieve euglycemia.
- Galactosyltransferase (GalT) activity was significantly reduced in metavanadate-treated and diabetic groups compared to controls.
- Electron microscopy revealed giant intracytoplasmic vacuoles and ultrastructural changes in metavanadate-treated groups; however, diabetic rats treated with metavanadate showed fewer advanced changes and more ring-like Golgi structures.
Conclusions:
- Metavanadate treatment did not normalize Golgi membrane preparations or marker enzyme activity in diabetic rats.
- Despite not normalizing key biochemical markers, metavanadate offered protection against severe ultrastructural damage in liver Golgi complexes of diabetic rats.
- Further research is needed to understand the protective mechanisms of vanadium compounds in diabetes-related cellular pathology.
